title: Radial versus femoral access for emergent percutaneous coronary intervention with adjunct glycoprotein IIb/IIIa inhibition in acute myocardial infarction--the RADIAL-AMI pilot randomized trial.
abstract: BACKGROUND
  Transradial percutaneous coronary intervention (PCI) results in fewer vascular complications, earlier ambulation, and improved patient comfort. Limited data exist for radial access in acute myocardial infarction, where reperfusion must occur quickly.
  
  
  METHODS
  In a multicenter pilot trial, 50 patients with myocardial infarction requiring either primary or rescue PCI were randomized to radial or femoral access. All operators had previously performed at least 100 transradial cases. Procedure times were prospectively recorded.
  
  
  RESULTS
  Thrombolysis was used in 66% of the cases and glycoprotein IIb/IIIa inhibitors in 94%. Crossover from radial to femoral access was required in one case. Percutaneous coronary intervention was performed in 47 patients, with stenting in 45. One procedural failure occurred with radial access because of inability to cross the occlusion. The time from local anesthesia to first balloon inflation was 32 (25th percentile 26, 75th percentile 38) minutes for radial access and 26 (22, 33) minutes for femoral access (P = .04). There were no significant differences in contrast use or fluoroscopy time. No patient experienced major bleeding or required transfusion. Doppler studies demonstrated 2 asymptomatic radial occlusions and 2 pseudoaneurysms (1 from each group). One patient in the femoral group died 2 days after PCI. At 30 days, there were no strokes or reinfarctions and no patient required bypass surgery or repeat PCI.
  
  
  CONCLUSIONS
  Primary and rescue PCI can be performed with high success rates using either radial or femoral access. Although radial access was associated with a longer time to first balloon inflation, the difference was small and likely not clinically significant. In patients without shock, major bleeding and vascular complications are infrequent with either access site despite the high use of thrombolysis and glycoprotein IIb/IIIa inhibitors.
authors.affiliation: St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. cantorw@smh.toronto.on.ca
authors.forename: Warren J
authors.initials: WJ
authors.lastname: Cantor
authors.forename: Geoff
authors.initials: G
authors.lastname: Puley
authors.forename: Madhu K
authors.initials: MK
authors.lastname: Natarajan
authors.forename: Vlad
authors.initials: V
authors.lastname: Dzavik
authors.forename: Mina
authors.initials: M
authors.lastname: Madan
authors.forename: Anne
authors.initials: A
authors.lastname: Fry
authors.forename: Hahn Hoe
authors.initials: HH
authors.lastname: Kim
authors.forename: James L
authors.initials: JL
authors.lastname: Velianou
authors.forename: Nurry
authors.initials: N
authors.lastname: Pirani
authors.forename: Bradley H
authors.initials: BH
authors.lastname: Strauss
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Chisholm
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy*; D010865:Pilot Projects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011446:Prospective Studies
chemical_list: D019039:Platelet Glycoprotein GPIIb-IIIa Complex